McCabe M, Kirton L, Khan M, Fenwick N, Strauss SJ, Valverde C, Mata C, Gaspar N, Luksch R, Longhi A, Dirksen U, Phillips M, Safwat A, Gelderblom H, Kuehne T, Kanerva J, Westwood AJ, Ferrari S, Whelan J, Wheatley K. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). American Society of Clinical Oncology: Journal of Clinical Oncology. 2022;40(Suppl 17):Abstract No. 11502
Anderton J, Moroz V, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Kaiser S, Fernández-Pinto M, Fenwick N, Evans A, Strauss S, Whelan J, Wheatley K, Brennan B. International randomised controlled trial for the treatment of newly diagnosed Ewing sarcoma family of tumours – Euro Ewing 2012 protocol. Trials. 2020;21:96.
McCabe MG, Kirton L, Khan M, Fenwick N, Dirksen U, Gaspar N, Kanerva J, Kuehne T, Longhi A, Luksch R, Mata C, Phillips M, Safwat A, Strauss SJ, Sundby Hall K, Valverde Morales CM, Westwood AJ, Winstanley M, Whelan J, Wheatley K. Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). American Society of Clinical Oncology: Journal of Clinical Oncology. 2020;38(Suppl 15):Abstract No. 11502.
McCabe MG, Moroz V, Khan M, Dirksen U, Evans A, Fenwick N, Gaspar N, Kanerva J, Kühne T, Longhi A, Luksch R, Mata C, Phillips M, Hall KS, Morales CMV, Westwood AJ, Winstanley M, Whelan J, Wheatley K, Consortium EE. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. American Society of Clinical Oncology: Journal of Clinical Oncology. 2019;37(Suppl 15):Abstract No. 11007
Moreno L, Moroz V, Owens C, Couanet DV, Gambert M, Castel V, van Eijkelenburg N, Zwaan CM, Murphy D, Morland B, Gray J, Marshall L, Burchill S, Chesler L, Peet A, Schleiermacher G, Fenwick N, Kearns P, Pearson ADJ, Page 25 of 40 V3.0, 01-Apr-2022 Wheatley K, editors. Temozolomide versus irinotecan-temozolomide for children with relapsed & refractory high risk neuroblastoma (RR-HRNB). Results of the BEACON-Neuroblastoma randomized phase II trial, an ITCC-SIOPEN trial. International Society of Pediatric Oncology; 2019; Lyon, France.
Khan J, Yap C, Clark R, Fenwick N, Marin D (2013): Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design. Trials 2013, 14(Suppl 1):P20
Earl, H.M. Vallier, A.L. Hiller, L. Fenwick, N. Young, J. Iddawela, M. Abraham, J. Hughes-Davies, L. Gounaris, I. McAdam, K. Houston, S. Hickish, T. Skene, S. Chan, S. Dean, S. Ritchie, D. Laing, R. Harries, M. Gallagher, C. Wishard, G. Dunn, J. Provenzano, E. Caldas, C. for the Neo-tAnGo Investigators. (2013), Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and aplictaxel for wmen with high-risk early breast cancer (Neo0tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. Lancet Oncol 2013. Published online December 19, 2013. http://dx.doi.org/10.1016/S1470-2045(13)70554-0 and online comment http://dx.doi.org/10.1016/S1470-2045(13)70584-9
Provenzano, E. A-L Vallier, A.L. Champ, R. Walland, K. Bowden, S. Grier, A, Fenwick, N. Abraham, J. Iddawela, M. Caldas, C. Hiller, L. Dunn, J. Earl, H.M. (2013), A central review of histology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer (2013) 108, 866–872. doi:10.1038/bjc.2012.547 www.bjcancer.com.
H. M. Earl, A. Vallier, L. Hiller, N. Fenwick, M. Iddawela, L. Hughes-Davies, E. Provenzano, K. McAdam, T. Hickish, C. Caldas, for NeotAnGo Investigators (2009), Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR), J Clin Oncol 27:15s, 2009 (suppl; abstr 522)